Wedbush Cuts Earnings Estimates for Apogee Therapeutics

Apogee Therapeutics Inc. (NASDAQ:APGE) – Analysts at Wedbush cut their Q3 2025 earnings per share estimates for Apogee Therapeutics in a note issued to investors on Monday, August 11th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($1.21) per share for the quarter, down from their previous estimate of ($0.96). Wedbush currently has a “Outperform” rating and a $90.00 price target on the stock. The consensus estimate for Apogee Therapeutics’ current full-year earnings is ($3.09) per share. Wedbush also issued estimates for Apogee Therapeutics’ Q4 2025 earnings at ($1.24) EPS, FY2025 earnings at ($4.53) EPS, Q1 2026 earnings at ($1.27) EPS, Q2 2026 earnings at ($1.18) EPS, Q3 2026 earnings at ($1.18) EPS, Q4 2026 earnings at ($1.13) EPS, FY2026 earnings at ($4.75) EPS, FY2027 earnings at ($4.75) EPS, FY2028 earnings at ($6.13) EPS and FY2029 earnings at ($5.99) EPS.

Several other research analysts also recently commented on APGE. BTIG Research boosted their price objective on shares of Apogee Therapeutics from $100.00 to $115.00 and gave the company a “buy” rating in a research report on Monday, July 7th. Guggenheim restated a “buy” rating and set a $116.00 price objective on shares of Apogee Therapeutics in a research report on Wednesday, July 2nd. Finally, Citigroup restated a “buy” rating on shares of Apogee Therapeutics in a research report on Monday, July 7th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $99.00.

Apogee Therapeutics Price Performance

Shares of APGE opened at $38.12 on Thursday. Apogee Therapeutics has a one year low of $26.20 and a one year high of $63.50. The company has a market cap of $1.76 billion, a P/E ratio of -9.23 and a beta of 1.43. The firm has a 50 day simple moving average of $40.16 and a two-hundred day simple moving average of $37.95.

Apogee Therapeutics (NASDAQ:APGE) last announced its quarterly earnings data on Monday, August 11th. The company reported ($1.13) EPS for the quarter, missing the consensus estimate of ($1.03) by ($0.10).

Insider Activity at Apogee Therapeutics

In other news, insider Carl Dambkowski sold 10,090 shares of the stock in a transaction on Wednesday, July 2nd. The stock was sold at an average price of $45.09, for a total value of $454,958.10. Following the completion of the transaction, the insider directly owned 238,998 shares in the company, valued at approximately $10,776,419.82. This represents a 4.05% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last three months, insiders sold 15,540 shares of company stock valued at $658,625. 42.77% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Nisa Investment Advisors LLC lifted its stake in shares of Apogee Therapeutics by 99.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 769 shares of the company’s stock valued at $33,000 after acquiring an additional 383 shares during the last quarter. Brooklyn Investment Group acquired a new stake in Apogee Therapeutics in the first quarter valued at $42,000. GF Fund Management CO. LTD. acquired a new stake in Apogee Therapeutics in the fourth quarter valued at $43,000. AlphaQuest LLC acquired a new stake in Apogee Therapeutics in the first quarter valued at $43,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Apogee Therapeutics by 18.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,779 shares of the company’s stock valued at $77,000 after purchasing an additional 272 shares during the period. 79.04% of the stock is currently owned by institutional investors.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.